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Hantavirus pulmonary syndrome (HPS) is
an emerging infectious disease, often character-
ized by rapid, dramatic clinical progression and
high case-fatality rates. Most cases in the United
States are caused by Sin Nombre virus (SNV);
like other viruses causing HPS, SNV has a single
rodent host belonging to the subfamily
Sigmodontinae (1). The virus is transmitted to
humans through inhalation of aerosolized feces,
urine, or saliva from infected rodents.
Since the initial outbreak in the Four
Corners region in 1993 (2), 217 cases of HPS were
reported in the United States as of May 28, 1999;
32 of these occurred before May 1993. These
cases have provided information on the clinical
symptoms, disease progression, and laboratory
characteristics of HPS. An incubation period of
2 to 3 weeks is typically followed by high fever,
myalgia, headache, fatigue, and gastrointestinal
symptoms (3,4). This phase is followed 4 to 6 days
later by abrupt onset of dyspnea and hypoxia,
typically associated with noncardiac pulmonary
edema and respiratory failure, requiring
hospitalization and intensive-care management
(4,5). Hypotension or shock with myocardial
depression is present in most patients; renal
dysfunction of varying severity is sometimes
observed. Common laboratory findings include
elevated hematocrit, leukocytosis with left shift
and immature myelocytes and immunoblasts,
and thrombocytopenia (6,7). The diagnosis is
confirmed by serologic testing for hantavirus
SNV immunoglobulin (Ig)M and IgG, although
reverse transcriptase polymerase chain reaction
(RT-PCR) or immunohistochemical analysis
(IHC) can also be done.
In a study of the prevalence of SNV antibody
in patients who had mild febrile illness during
the 1993 HPS outbreak, asymptomatic and mild
infections were uncommon (8). This observation
contrasts with reports of hantaviruses that cause
hemorrhagic fever with renal syndrome; mild
disease can occur after infection with Hantaan
virus and is predominately associated with
Puumala virus infections (9,10). Since May 1993,
five persons with mild acute HPS illness have
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Hantavirus pulmonary syndrome (HPS) occurs in most infections with Sin Nombre
virus and other North American hantaviruses. We report five cases of acute hantavirus
infection that did not fit the HPS case definition. The patients had characteristic
prodromal symptoms without severe pulmonary involvement. These cases suggest that
surveillance for HPS may need to be expanded.702 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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been identified; one was a 4-year-old boy whose
case has been described (11). We describe the
other four cases, two of which were detected in
1998 and one in 1999.
HPS is clinically defined as a febrile illness
(temperature >38.3°C) with bilateral diffuse
infiltrates that cause respiratory compromise
requiring supplemental oxygen within 72 hours
of hospitalization (12). A case may also be defined
postmortem as an unexplained, fatal respiratory
illness,  with noncardiogenic pulmonary edema
of unknown cause. Clinically suspected cases are
confirmed by fulfilling one of three criteria at a
reference laboratory: detection of hantavirus-
specific IgM or rising titers of IgG antibodies, or
hantavirus-specific RNA sequence by RT-PCR,
or hantavirus antigens in tissues by IHC.
These four atypical cases were identified
through the National HPS Surveillance System,
although they did not meet the clinical criteria
for HPS. In Patients 2 and 3, infection with SNV
was suspected early in the illness, and sera were
tested promptly for hantavirus antibodies.
Serum from Patient 1 was tested for SNV
antibody retrospectively, after a friend with a
common exposure history was diagnosed with
HPS. Acute- and convalescent-phase sera from
each patient were also tested at CDC for
hantavirus IgM and IgG antibodies by using a
panel of prototypic hantavirus strains (13). Cases
were confirmed as acute SNV infections if there
were substantial titers of anti-SNV IgM and
either substantial acute-phase titers of IgG or a
fourfold rise in convalescent-phase IgG titers.
Case Report 1
A 38-year-old previously healthy man from
Nevada visited a local emergency room in
October 1993 with a 3-day history of fever,
headache, fatigue, malaise, dizziness, progres-
sive myalgia, dry cough, and shortness of breath
(Table). His temperature was 38.3°C, pulse 103
per minute, and blood pressure 130/77 mm Hg. His
oxygen saturation was 85% on room air, improving
to 94% on 2 liters of oxygen by nasal cannula.
Except for frontal sinus tenderness, his physical
examination was otherwise unremarkable.
Approximately 2 weeks later, a friend of the
patients died of a respiratory illness diagnosed
as HPS. A case investigation of all household and
social contacts led retrospectively to the
diagnosis of acute hantavirus infection in the
patient, as demonstrated by positive SNV IgM
and IgG titers. The patient and his friend had
worked together at a ranch in rural Nevada,
where they slept for 2 days in a rodent-infested
guest house (14).
Case Report 2
A 36-year-old woman from California visited
her physician in July 1998 with a 2-day history of
fever, headache, and malaise. Her temperature
was 37.5°C, pulse 130 per min, and blood
pressure 90/60/mm Hg. Physical examination
was unremarkable.
Two days later, she visited the emergency
room for the same complaints, as well as myalgia,
dry cough accompanied by substernal burning
and pain, sore throat, vomiting, and photophobia
(Table). She was not in acute respiratory
distress. An infectious mononucleosis test was
positive. She was diagnosed with a viral syndrome
probably secondary to mononucleosis and
dehydration, treated with intravenous fluids,
and discharged. Her clinical course improved
without hospitalization.
The patient worked as a registered nurse and
lived on a ranch. She had no history of recent
travel. She reported three exposures to rodent
excreta in the month before becoming ill, twice
while cleaning a barn and once while cleaning
her mobile home. Because of this history, she was
tested for SNV antibodies on day 2 of illness. This
acute-phase serum, as well as a convalescent-
phase serum, tested positive for both SNV IgM
and IgG antibodies.
Case Report 3
A previously healthy 19-year-old man visited
a local Colorado emergency room in June 1999
with a 2-day history of fever, chills, myalgia,
nausea, and vomiting, but no shortness of
breath. His vital signs included a temperature of
39.5°C, pulse of 93 per minute, blood pressure
114/71 mm Hg, and oxygen saturation of 89.9%
on room air. A platelet count was 96,000/mm3. A
chest X-ray was unremarkable. A diagnosis of
HPS was suspected because of a history of rodent
exposure in the community, with two recent fatal
cases, but the patient refused hospitalization.
The patient was admitted 2 days later after
his initial serum specimen was noted to have
SNV IgM and IgG antibodies. He felt better,
although he remained febrile and had developed
a slight cough. A repeat chest X-ray was initially
reported as normal but was retrospectively read703 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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Table. Characteristics of five acute cases of Sin Nombre Virus infection without pulmonary syndrome, 1993–1999
Case 1, 1993 Case 2, 1998 Case 3, 1999 Case 4, 1998a Case 5, 1993b
Age (yr) 38 36 19 32 4
S e x MF MMM
Race White White White White American
  Indian
State Nevada California Colorado Utah New Mexico
Hospitalized No No Yes Yes No
Symptoms
Fever +c + +++
Headache + + - + -
Malaise + + - - -
Myalgia + + + + -
Cough + + + - +
Shortness of breath + - - - -
Chest/substernal pain - + - - -
Sore throat - + - - NRd
Nausea/vomiting + + + - NR
Dizziness + - + - NR
Photophobia - + -
Abdominal pain - - - - NR
Diarrhea - - - - NR
Arthralgia - - - + NR
Vital signs
Max temp (ºF) 102.5 104.0 103.1 102.8 100.6
Blood pressure normal normal normal normal NR
Lowest O2 sat. (RAe) 85% 94% 89.9% 94% NR
Laboratory results
Highest Hct (%) 47.0 44.7 50.2 44.4 40.2
Highest WBC 9,100 8,000 10,200 7,300 NRf
% seg. neutrophils 68 40 39 88
% bands 9 30 24
% lymphocytes 19 14 20 7
% atypical lymphocytes NR 4 NR NR
Lowest platelet (/mm3) 127,000 115,000 28,000 163,000 NRg
Highest SGOTh (U/L) NR 81 NR 26 NR
Highest LDHi (U/L) NR 337 488 240 NR
Lowest albumin (g/dL) NR 3.1 NR 4.3 NR
Chest X-ray 2-cm normal Mild normal NR
  granuloma   left lower
  lobe
  infiltrate
Anti-SNVj antibody
IgM positive positive positive positive positive
IgG positive positive positive positive positive
aObtained from Zavasky D-M, Hjelle B, Peterson M, et al. Acute infection with Sin Nombre hantavirus without pulmonary
edema. Clin Infect Dis, in press.
bObtained from Armstrong et al., 1995 (12).
c+, present; -, absent.
dNR = not recorded or obtained.
eRA = room air.
fPatient did not have leukocytosis.
gPatient did not have thrombocytopenia.
hSGOT = serum glutamic oxalacetic acid.
iLDH = lactic dehydrogenase.
jSNV = Sin Nombre virus.704 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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as having a slight left lower lobe interstitial
infiltrate. His symptoms gradually resolved and
he was discharged 2 days after admission.
Conclusions
These patients are among the first adults in
the United States to have had acute SNV
infections resulting in illnesses less severe than
HPS; a fourth is being described elsewhere
(Table). These patients had the characteristic
HPS-like prodromal symptoms of high fever,
headache, and mylagia. Some of the other typical
features of HPS (malaise, nausea, vomiting,
dizziness, cough, chest pain) were also observed.
Patient 1 initially had signs and symptoms of
pulmonary involvement, documented by low
oxygen saturation. In contrast, Patients 2 and 3
did not have respiratory distress, although
Patient 3 had one oxygen saturation measure-
ment of 89.5% on room air. All four patients had
normal lung findings on physical examination
and characteristic diffuse bilateral interstitial
edema was not seen on chest X-rays.
Several of the typical laboratory findings of
HPS were noted, including a left shift on the
white blood count differential, atypical lympho-
cytes, mildly elevated serum glutamic oxalacetic
acid or lactic dehydrogenase, and low albumin.
All the reported patients had unequivocal
thrombocytopenia, and Patient 4 had a decreasing
platelet count. The hematocrit of Patient 2 rose
from 42.3% to 44.7% during her acute illness,
then decreased to 36.3%, suggesting a period of
substantial hemoconcentration, as seen in HPS.
All three patients became ill in areas of the
United States where reservoirs of other known
pathogenic U.S. hantaviruses are not found and
where all RT-PCR-typed HPS cases have been
caused by SNV.
During the initial 1993 outbreak, an
intensive search for SNV IgM and IgG antibodies
was conducted among household contacts of
patients (15), as well as among patients with
acute fever and myalgia resembling HPS
prodromal symptoms (8). IgM antibodies
reacting with SNV were not found in the study
population, which suggests that mild acute
hantavirus infections were uncommon.
The first case of mild SNV illness with
positive SNV IgM and IgG antibodies was
described in a 4-year-old boy who had upper
respiratory infection symptoms and otitis media
but no other abnormal laboratory findings (11).
Mild cases of HPS have been observed in
patients who did not have severe pulmonary
disease or respiratory failure. In addition, a few
patients with HPS with an initial normal chest
X-ray have been described (16). However, chest
X-rays 24 to 48 hours later demonstrated
interstitial or alveolar edema in all these
patients. These cases of mild HPS must be
distinguished from the three cases reported in
this article, which had no or minimal radiologic
pulmonary involvement.
It is unclear why severe respiratory distress,
pulmonary edema, and hypotension or shock, the
hallmarks of HPS, did not develop in these
patients. Histopathologic and immunologic studies
of acute HPS patients have shown antibodies,
significant CD8 and CD4 T-lymphocyte activation,
and lymphokine involvement, suggesting the
hypothesis that HPS is an immunopathologic
response to hantavirus infection (6,7,13,17,18).
Patients with mild SNV illness may have a
weaker immune response to the virus than
patients whose illness progresses to HPS. In
addition, integrins expressed on platelets and
endothelial cells have recently been implicated
as a vehicle for HPS-associated SNV and NY-1
cellular entry and pathogenicity (19). Physi-
ologic or genetic variations in these receptor
molecules may provide another potential explana-
tion for differing hantavirus pathogenesis.
Virologic factors may also play a role in the
development of mild illness. Like the hantaviruses
that cause a clinical spectrum of hemorrhagic
fever with renal syndrome, less pathogenic
strains of SNV or other American hantaviruses
may not yet have been characterized. Further
virologic, molecular, and immunologic analyses
of these and other cases may provide better
insights into the pathophysiologic mechanisms
of mild SNV disease.
Domestic exposure to rodent excreta contin-
ues to be a major risk factor for contracting HPS.
Public health education of risk-reducing mea-
sures against hantavirus infection should remain a
high priority. Moreover, SNV infection should be
considered in the differential diagnoses of
patients with nonspecific febrile illness and a
history of possible exposure to rodents.705 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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